The results of the study suggested that shRNA-MC RVG-EV therapy could not only decrease alpha-synuclein aggregation in brain but also could reduce the formation of alpha-synuclein fibrils/aggregates in organs affected in pre-clinical stages of Parkinson’s disease. This evidence concerns the gene SNCA and Parkinson disease.